Denali Therapeutics gains FDA approval for Hunter syndrome drug AVLAYAH

March 25, 2026 11:50 AM

Denali Therapeutics Inc. (NASDAQ: DNLI) received U.S. Food and Drug Administration accelerated approval for AVLAYAH (tividenofusp alfa-eknm), an enzyme replacement ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found